Table 1 List of FDA-approved kinase inhibitors and their drug targets
From: Kinase-targeted cancer therapies: progress, challenges and future directions
Drug target | Protein substrate | Drug |
|---|---|---|
ALK | Tyrosine | Crizotinib, Ceritinib, Alectinib, Brigatinib |
BCR–Abl | Tyrosine | Bosutinib, Dasatinib, Imatinib, Nilotinib, Ponatinib |
B-Raf | Serine/threonine | Vemurafenib, Dabrafenib |
BTK | Tyrosine | Ibrutinib |
CDK family | Serine/threonine | Palbociclib, Sorafenib, Ribociclib |
c-Met | Tyrosine | Crizotinib, Cabozantinib |
EGFR family | Tyrosine | Gefitinib, Erlotinib, Lapatinib, Vandetanib, Afatinib, Osimertinib |
JAK family | Tyrosine | Ruxolitinib, Tofacitinib |
MEK1/2 | Dual specificity | Trametinib |
PDGFR α/β | Tyrosine | Axitinib, Gefitinib, Imatinib, Lenvatinib, Nintedanib, Pazopanib, Regorafenib, Sorafenib, Sunitinib |
RET | Tyrosine | Vandetanib |
Src family | Tyrosine | Bosutinib, Dasatinib, Ponatinib, Vandetanib |
VEGFR family | Tyrosine | Axitinib, Lenvatinib, Nintedanib, Regorafenib, Pazopanib, Sorafenib, Sunitinib |